Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:KITE's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

KITE Guru Trades in Q1 2017

John Hussman 35,000 sh (New)
Leon Cooperman 53,761 sh (New)
Columbia Wanger 451,674 sh (New)
Steven Cohen 819,900 sh (+235.03%)
» More
Q2 2017

KITE Guru Trades in Q2 2017

Joel Greenblatt 5,320 sh (New)
Paul Tudor Jones 5,055 sh (New)
Andreas Halvorsen 480,155 sh (New)
Steven Cohen 400,000 sh (unchged)
Leon Cooperman Sold Out
John Hussman Sold Out
Columbia Wanger 368,254 sh (-18.47%)
Steven Cohen 437,969 sh (-46.58%)
» More
Q3 2017

KITE Guru Trades in Q3 2017

Mario Gabelli 193,350 sh (New)
Jim Simons 778,300 sh (New)
Prem Watsa 6,100 sh (New)
Joel Greenblatt 61,725 sh (+1060.24%)
Paul Tudor Jones Sold Out
Andreas Halvorsen Sold Out
Columbia Wanger Sold Out
Steven Cohen Sold Out
» More
Q4 2017

KITE Guru Trades in Q4 2017

Joel Greenblatt Sold Out
Prem Watsa Sold Out
Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KITE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Prem Watsa 2017-12-31 Sold Out 0.09%$179.79 - $179.79 $ 179.790%0
Mario Gabelli 2017-12-31 Sold Out 0.22%$179.79 - $179.79 $ 179.790%0
Joel Greenblatt 2017-12-31 Sold Out 0.16%$179.79 - $179.79 $ 179.790%0
Mario Gabelli 2017-09-30 New Buy0.22%$101.13 - $179.74 $ 179.7930%193,350
Joel Greenblatt 2017-09-30 Add 1060.24%0.15%$101.13 - $179.74 $ 179.7930%61,725
Prem Watsa 2017-09-30 New Buy0.09%$101.13 - $179.74 $ 179.7930%6,100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Kite Pharma Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 2834
Compare:HKSE:02269, NAS:JUNO, NAS:BLUE, NAS:JAZZ, NAS:BIVV, NAS:ALKS, NAS:SGEN, OCSE:GEN, NAS:NBIX, NAS:BGNE, NAS:SAGE, NAS:ALNY, NAS:BMRN, NAS:EXEL, XKRX:215600, NAS:IONS, TSE:4587, OCSE:NZYM B, XBRU:UCB, NAS:TECH » details
Traded in other countries:KT5.Germany,
Headquarter Location:USA
Kite Pharma Inc is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells.

Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.

Top Ranked Articles about Kite Pharma Inc

Where Are Biotech Industry Vets Taking a Seat at the Table Right Now? Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets
Within the last 12 months we have seen some of the largest biopharma buyouts in history. Last year, Gilead Sciences Inc. (NASDAQ:GILD) acquired Kite Pharma Inc. (NASDAQ:KITE) in a deal that was valued at nearly $12 billion! This year we’ve already begun to see the trend continue after Bioverativ Inc. (NASDAQ:BIVV) was acquired by French biotech company, Sanofi SA ADR (NYSE:SNY) in an $11.6 billion deal. Furthermore, announcements that Celgene Corp. (NASDAQ:CELG) would acquire Juno Therapeutics Inc. (NASDAQ:JUNO) and AbbVie, Inc. (NYSE:ABBV) could seek deals to build onto or complement its early-stage Alzheimer's disease pipeline have kept the fire piping hot for biotech buyouts. With this in mind, there’s no doubt that the future could hold even larger deals in the biopharma space considering immense advancements that this sector is seeing right now. Read more...
Prem Watsa Trims IBM, Berkshire Hathaway The guru’s largest sales of the 4th quarter
Prem Watsa (Trades, Portfolio), founder, chairman and CEO of Fairfax Financial Holdings,  sold shares of the following stocks during the fourth quarter. Read more...
5 Companies Reach 52-Week Highs Multiple companies have achieved recently yearly highs
IMS Health Holdings Inc. (NYSE:IMS) reached the 52-week high of $31.34 Read more...
Mario Gabelli Exits Kite Pharma, Trims Time Warner The guru's largest sales of the 4th quarter
GAMCO Investors leader Mario Gabelli (Trades, Portfolio) sold shares of the following stocks in the fourth quarter. Read more...
Five Companies Hit 52-Week Highs Multiple companies have all managed to reach yearly highs recently
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-week highs. Read more...
Five Companies Hit 52-Week Highs Recently, a number of companies have all managed to achieve yearly highs.
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs. Read more...
Mario Gabelli’s Top 5 New Buys for the 3rd Quarter Guru releases quarterly portfolio
GAMCO Investors leader Mario Gabelli (Trades, Portfolio) added 45 stocks to his portfolio in the third quarter. Read more...
5 Companies Achieve 52-Week Highs International Flavors & Fragrances leads milestone list
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
Let’s Talk About CAR-T A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
For those interested in staying up to date with the latest developments in biotechnology it is impossible to overlook the developments of chimeric antigen receptor therapy (CAR-T) and the potential it holds for treating cancer. The most pivotal moment came on Aug. 30 when Novartis (NVS) announced approval for Kymriah™ (tisagenlecleucel) for treating children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Read more...
Andreas Halvorsen Scoops Up Abeona Therapeutics Guru invests in biopharmaceutical company
Viking Global Investors LP Chief Investment Officer Andreas Halvorsen (Trades, Portfolio) established a stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) on Sept. 22, according to GuruFocus real-time picks. Read more...

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $32.14
EPS (TTM) $ -6.91
52-Week Range $39.82 - 179.95
Shares Outstanding (Mil)57.36

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 46 239 645 1,144
EBIT (Mil $) -448 -362 -153 76
EBITDA (Mil $) -441 -354 -153 76
EPS ($) -8.27 -6.42 -2.46 1.34
EPS without NRI ($) -8.27 -6.42 -2.46 1.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}